Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Neurosci
2013 Mar 20;43:435-43. doi: 10.1021/cn300144v.
Show Gene links
Show Anatomy links
Quantum dot conjugates of GABA and muscimol: binding to α1β2γ2 and ρ1 GABA(A) receptors.
Gussin HA
,
Tomlinson ID
,
Cao D
,
Qian H
,
Rosenthal SJ
,
Pepperberg DR
.
???displayArticle.abstract??? GABAA receptors are ligand-gated ion channels that mediate inhibitory synaptic signaling in the CNS. Fluorescent probes with the ability to target these receptors can provide insights into receptor location, distribution and dynamics in live cells, while revealing abnormalities in their distribution and dynamics that could occur in a variety of diseases. We have developed fluorescent probes of GABAA receptors that are composed of a CdSe/ZnS core-shell nanocrystal (quantum dot; qdot) conjugated to pegylated derivatives of the GABA receptor agonists GABA and muscimol (GABA-qdots and muscimol-qdots, respectively). Quantitative fluorescence imaging was used to analyze the binding activity of these conjugates to α1β2γ2 GABAA and ρ1 GABAA receptors expressed in Xenopus oocytes. The selectivity of these conjugates for α1β2γ2 GABAA and ρ1 GABAA receptors was determined by their ability to compete with the antagonists bicuculline and methyl-(1,2,3,6-tetrahydropyridin-4-yl)phosphinic acid (TPMPA). Both GABA- and muscimol-qdots exhibited robust binding to both α1β2γ2 and ρ1 GABAA receptors. At α1β2γ2 receptors, pretreatment with bicuculline reduced conjugate binding by ≥8-fold on average, an extent far exceeding the reduction produced by TPMPA (~30%). Conversely, at ρ1 receptors, pretreatment with TPMPA inhibited binding by ~10-fold, an extent greatly exceeding the change produced by bicuculline (~50% or less). These results indicate specific binding of muscimol-qdots and GABA-qdots to α1β2γ2 GABAA and ρ1 GABAA receptors in a manner that preserves the respective pharmacological sensitivities of these receptors to TPMPA and bicuculline, and encourage the use of qdot-conjugated neurotransmitter analogs as labeling agents at GABAA receptors.
Anikeeva,
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response.
2006, Pubmed
Anikeeva,
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response.
2006,
Pubmed
Bentzen,
Surface modification to reduce nonspecific binding of quantum dots in live cell assays.
2005,
Pubmed
Biju,
Semiconductor quantum dots and metal nanoparticles: syntheses, optical properties, and biological applications.
2008,
Pubmed
Bouzigues,
Single quantum dot tracking of membrane receptors.
2007,
Pubmed
Bruchez,
Semiconductor nanocrystals as fluorescent biological labels.
1998,
Pubmed
Chebib,
(3-Aminocyclopentyl)methylphosphinic acids: novel GABA(C) receptor antagonists.
2007,
Pubmed
,
Xenbase
Chebib,
GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology.
2000,
Pubmed
Chebib,
GABAC receptor ion channels.
2004,
Pubmed
Cutting,
Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina.
1991,
Pubmed
,
Xenbase
Dahan,
Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking.
2003,
Pubmed
Doughty,
Benextramine-neuropeptide Y receptor interactions: contribution of the benzylic moieties to [3H]neuropeptide Y displacement activity.
1993,
Pubmed
Drew,
Bicuculline- and baclofen-insensitive gamma-aminobutyric acid binding to rat cerebellar membranes.
1992,
Pubmed
Enz,
Molecular composition of GABAC receptors.
1998,
Pubmed
,
Xenbase
Feigenspan,
Differential pharmacology of GABAA and GABAC receptors on rat retinal bipolar cells.
1994,
Pubmed
Goldman,
Multiplexed toxin analysis using four colors of quantum dot fluororeagents.
2004,
Pubmed
Gussin,
Binding of muscimol-conjugated quantum dots to GABAC receptors.
2006,
Pubmed
,
Xenbase
Gussin,
GABAC receptor binding of quantum-dot conjugates of variable ligand valency.
2010,
Pubmed
,
Xenbase
Jaiswal,
Imaging single events at the cell membrane.
2007,
Pubmed
Johnston,
GABAc receptors: relatively simple transmitter -gated ion channels?
1996,
Pubmed
Kovtun,
Visualization of the cocaine-sensitive dopamine transporter with ligand-conjugated quantum dots.
2011,
Pubmed
Kumar,
Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships.
2008,
Pubmed
,
Xenbase
Macdonald,
GABAA receptor channels.
1994,
Pubmed
Martínez-Delgado,
An Update on GABAρ Receptors.
2010,
Pubmed
Mason,
Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation.
2005,
Pubmed
McBride,
Structural basis for near unity quantum yield core/shell nanostructures.
2006,
Pubmed
Medintz,
Quantum dot bioconjugates for imaging, labelling and sensing.
2005,
Pubmed
Olsen,
International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update.
2008,
Pubmed
Olsen,
GABA A receptors: subtypes provide diversity of function and pharmacology.
2009,
Pubmed
Orndorff,
Quantum dot ex vivo labeling of neuromuscular synapses.
2008,
Pubmed
Pathak,
Characterization of the functional binding properties of antibody conjugated quantum dots.
2007,
Pubmed
Polenzani,
Expression of mammalian gamma-aminobutyric acid receptors with distinct pharmacology in Xenopus oocytes.
1991,
Pubmed
,
Xenbase
Qian,
A comparison of GABAC and rho subunit receptors from the white perch retina.
1997,
Pubmed
,
Xenbase
Qian,
A single amino acid in the second transmembrane domain of GABA rho subunits is a determinant of the response kinetics of GABAC receptors.
1999,
Pubmed
,
Xenbase
Qian,
Molecular and pharmacological properties of GABA-rho subunits from white perch retina.
1998,
Pubmed
,
Xenbase
Ragozzino,
Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
1996,
Pubmed
,
Xenbase
Rajan,
Ligand-bound quantum dot probes for studying the molecular scale dynamics of receptor endocytic trafficking in live cells.
2008,
Pubmed
Robinson,
Probing lectin and sperm with carbohydrate-modified quantum dots.
2005,
Pubmed
Rosenthal,
Targeting cell surface receptors with ligand-conjugated nanocrystals.
2002,
Pubmed
,
Xenbase
Sedelnikova,
Mapping the rho1 GABA(C) receptor agonist binding pocket. Constructing a complete model.
2005,
Pubmed
Sieghart,
Subunit composition, distribution and function of GABA(A) receptor subtypes.
2002,
Pubmed
Tomlinson,
Universal polyethylene glycol linkers for attaching receptor ligands to quantum dots.
2006,
Pubmed
Tomlinson,
Imaging GABAc receptors with ligand-conjugated quantum dots.
2007,
Pubmed
,
Xenbase
Tomlinson,
Biotin tethered homotryptamine derivatives: high affinity probes of the human serotonin transporter (hSERT).
2011,
Pubmed
,
Xenbase
Tomlinson,
Peptide-conjugated quantum dots: imaging the angiotensin type 1 receptor in living cells.
2005,
Pubmed
Vu,
Activation of membrane receptors by a neurotransmitter conjugate designed for surface attachment.
2005,
Pubmed
,
Xenbase
Willner,
Nanoparticle-enzyme hybrid systems for nanobiotechnology.
2007,
Pubmed
Xie,
2-Aminoethyl methylphosphonate, a potent and rapidly acting antagonist of GABA(A)-ρ1 receptors.
2011,
Pubmed
,
Xenbase
Yamamoto,
Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ1 receptor.
2012,
Pubmed
,
Xenbase